Prima BioMed Ltd (NASDAQ:IMMP) Stock Rated “Hold” by Sell-Side Analysts

Shares of Prima BioMed Ltd (NASDAQ:IMMP) have been given an average rating of “Hold” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $110.00.

Several equities research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a research report on Tuesday, October 6th. Jefferies Financial Group raised shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th.

Prima BioMed Stock Down 0.3%

Prima BioMed stock opened at $3.20 on Monday. The business has a 50 day moving average of $6.17 and a 200-day moving average of $7.66. Prima BioMed has a 1 year low of $3.06 and a 1 year high of $70.60.

Prima BioMed (NASDAQ:IMMP) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The business had revenue of $3.68 million for the quarter.

Prima BioMed Company Profile

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments.